Literature DB >> 23676511

Determination of the external contamination and cross-contamination by cytotoxic drugs on the surfaces of vials available on the Swiss market.

Sandrine Fleury-Souverain1, Susanne Nussbaumer, Marc Mattiuzzo, Pascal Bonnabry.   

Abstract

INTRODUCTION: The external contamination and cross-contamination by cytotoxic drugs on the surface (outside and septum) of 133 vials from various manufacturers and available on the Swiss market were evaluated. All of the tested vials contained one of the following active ingredients: cyclophosphamide, cytarabine, doxorubicin, epirubicin, etoposide phosphate, gemcitabine, ifosfamide, irinotecan, methotrexate or vincristine. METHODS AND MATERIALS: The validated wiping liquid chromatography-mass spectrometry method used in this study allowed for the simultaneous determination of these 10 cytotoxic drugs in less than 30 min.
RESULTS: External contamination by cytotoxic drugs was detected on 63% of tested vials (outside and septum). The highest contamination level was observed on etoposide phosphate vials with 1896.66 ng of active ingredient on the outside of the vial. Approximately 20% of the contaminated vials had greater than 10 ng of cytotoxic drugs. Chemical contamination on the septum was detected on 38% of the vials. No contamination or very low levels of cytotoxic drugs, less than 1 ng per vial, were detected on the vials protected by plastic shrink-wrap. Traces of cytotoxic drugs different from the active ingredient were detected on 35% of the tested vials.
CONCLUSION: Handling cytotoxic vials with gloves and having a procedure for the decontamination of vials are of the utmost importance for reducing exposure to cytotoxic drugs. Moreover, manufacturers must improve their procedures to provide products free from any contamination.

Entities:  

Keywords:  Cytotoxic drugs; cross-contamination; external chemical contamination; packaging; vials

Mesh:

Substances:

Year:  2013        PMID: 23676511     DOI: 10.1177/1078155213482683

Source DB:  PubMed          Journal:  J Oncol Pharm Pract        ISSN: 1078-1552            Impact factor:   1.809


  7 in total

1.  Field evaluation of onsite near real-time monitors for surface contamination by 5-fluorouracil.

Authors:  Jerome P Smith; Deborah Sammons; Shirley Robertson; Edward Krieg; John Snawder
Journal:  J Oncol Pharm Pract       Date:  2018-06-27       Impact factor: 1.809

Review 2.  Environmental monitoring by surface sampling for cytotoxics: a review.

Authors:  Petit Marie; Curti Christophe; Roche Manon; Montana Marc; Bornet Charleric; Vanelle Patrice
Journal:  Environ Monit Assess       Date:  2017-01-06       Impact factor: 2.513

3.  Hazardous Drug Contamination of Drug Preparation Devices and Staff: A Contamination Study Simulating the Use of Chemotherapy Drugs in a Clinical Setting.

Authors:  Evan Call; Brian Bill; Chad McLean; Nathan Call; Allyn Bernkopf; Craig Oberg
Journal:  Hosp Pharm       Date:  2017-08-20

4. 

Authors:  Annaelle Soubieux; Caroline Plante; Johann-François Ouellette-Frève; Audrey Chouinard; Jean-François Bussières
Journal:  Can J Hosp Pharm       Date:  2020-02-01

5.  Environmental assessment of cytotoxic drugs in the Oncology Center of Cyprus.

Authors:  Elpidoforos S Soteriades; Sofia C Economidou; Artemis Tsivitanidou; Petros Polyviou; Amanda Lorimer; Nikos Katodritis; Stavroula Theophanous-Kitiri
Journal:  PLoS One       Date:  2020-03-05       Impact factor: 3.240

Review 6.  Closed-system drug-transfer devices plus safe handling of hazardous drugs versus safe handling alone for reducing exposure to infusional hazardous drugs in healthcare staff.

Authors:  Kurinchi Selvan Gurusamy; Lawrence Mj Best; Cynthia Tanguay; Elaine Lennan; Mika Korva; Jean-François Bussières
Journal:  Cochrane Database Syst Rev       Date:  2018-03-27

7.  Evaluation of external contamination on the vial surfaces of some hazardous drugs that commonly used in Chinese hospitals and comparison between environmental contamination generated during robotic compounding by IV: Dispensing robot vs. manual compounding in biological safety cabinet.

Authors:  Hao Ml; Wang T; Zhu Jq; Song Yj; Gong Tj; Zou Lk; Liu J; Yan Jf
Journal:  J Oncol Pharm Pract       Date:  2021-06-24       Impact factor: 1.416

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.